Mainz Biomed Statistics
Total Valuation
Mainz Biomed has a market cap or net worth of $6.26 million. The enterprise value is $7.40 million.
Important Dates
The last earnings date was Friday, September 26, 2025, before market open.
Earnings Date | Sep 26, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Mainz Biomed has 4.09 million shares outstanding. The number of shares has increased by 351.86% in one year.
Current Share Class | 4.09M |
Shares Outstanding | 4.09M |
Shares Change (YoY) | +351.86% |
Shares Change (QoQ) | +128.23% |
Owned by Insiders (%) | 1.25% |
Owned by Institutions (%) | 3.03% |
Float | 3.32M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 5.38 |
Forward PS | n/a |
PB Ratio | 2.55 |
P/TBV Ratio | n/a |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 11.22 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.52, with a Debt / Equity ratio of 1.23.
Current Ratio | 0.52 |
Quick Ratio | 0.35 |
Debt / Equity | 1.23 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -26.47 |
Financial Efficiency
Return on Equity (ROE) | n/a |
Return on Assets (ROA) | -114.35% |
Return on Invested Capital (ROIC) | -214.19% |
Return on Capital Employed (ROCE) | -437.77% |
Revenue Per Employee | $25,382 |
Profits Per Employee | -$729,658 |
Employee Count | 26 |
Asset Turnover | 0.07 |
Inventory Turnover | 0.42 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -88.62% in the last 52 weeks. The beta is 0.25, so Mainz Biomed's price volatility has been lower than the market average.
Beta (5Y) | 0.25 |
52-Week Price Change | -88.62% |
50-Day Moving Average | 1.62 |
200-Day Moving Average | 3.04 |
Relative Strength Index (RSI) | 43.93 |
Average Volume (20 Days) | 472,857 |
Short Selling Information
The latest short interest is 89,503, so 2.19% of the outstanding shares have been sold short.
Short Interest | 89,503 |
Short Previous Month | 101,950 |
Short % of Shares Out | 2.19% |
Short % of Float | 2.70% |
Short Ratio (days to cover) | 1.53 |
Income Statement
In the last 12 months, Mainz Biomed had revenue of $659,935 and -$18.97 million in losses. Loss per share was -$8.39.
Revenue | 659,935 |
Gross Profit | 445,434 |
Operating Income | -16.70M |
Pretax Income | -18.97M |
Net Income | -18.97M |
EBITDA | -16.15M |
EBIT | -16.70M |
Loss Per Share | -$8.39 |
Full Income Statement Balance Sheet
The company has $1.91 million in cash and $3.09 million in debt, giving a net cash position of -$1.18 million or -$0.29 per share.
Cash & Cash Equivalents | 1.91M |
Total Debt | 3.09M |
Net Cash | -1.18M |
Net Cash Per Share | -$0.29 |
Equity (Book Value) | 2.52M |
Book Value Per Share | 0.62 |
Working Capital | -2.90M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$15.46 million and capital expenditures $14,588, giving a free cash flow of -$15.45 million.
Operating Cash Flow | -15.46M |
Capital Expenditures | 14,588 |
Free Cash Flow | -15.45M |
FCF Per Share | -$3.78 |
Full Cash Flow Statement Margins
Gross Margin | 67.50% |
Operating Margin | -2,530.90% |
Pretax Margin | -2,874.69% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Mainz Biomed does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -351.86% |
Shareholder Yield | -351.86% |
Earnings Yield | -305.02% |
FCF Yield | -248.36% |
Analyst Forecast
The average price target for Mainz Biomed is $14.00, which is 815.03% higher than the current price. The consensus rating is "Buy".
Price Target | $14.00 |
Price Target Difference | 815.03% |
Analyst Consensus | Buy |
Analyst Count | 2 |
Revenue Growth Forecast (5Y) | 143.03% |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
The last stock split was on December 3, 2024. It was a reverse split with a ratio of 1:40.
Last Split Date | Dec 3, 2024 |
Split Type | Reverse |
Split Ratio | 1:40 |
Scores
Mainz Biomed has an Altman Z-Score of -19.22 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -19.22 |
Piotroski F-Score | 4 |